Sympathetic activation in heart failure and its treatment with β- blockade

Archives of Internal Medicine

Volumn 159, Issue 3, 1999, Pages 225-234

  Pepper, Gregory S ^a   Lee, Richard W ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CATECHOLAMINE; METOPROLOL; NORADRENALIN;

BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; EXERCISE TOLERANCE; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE REMODELING; HEMODYNAMICS; HUMAN; IMMUNE SYSTEM; MORBIDITY; MORTALITY; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SYMPATHETIC TONE;

ADRENERGIC BETA-ANTAGONISTS; HEART CONDUCTION SYSTEM; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HORMONES; HUMANS; MULTICENTER STUDIES; NEUROPEPTIDES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SYMPATHETIC NERVOUS SYSTEM;

EID: 0033535129     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.3.225     Document Type: Review

References (65)

1. Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J. 1997;18: 208-225.
2. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality: CONSENSUS Trial Study Group. Circulation. 1990;82:1730-1736.
3. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
4. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257-1263.
5. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993; 342:1441-1446.
6. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773.
7. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-380.
8. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334:1349-1355.
9. Packer M. How should physicians view heart failure? the philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol. 1993;71:3C-11C.
10. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20: 248-254.
11. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986; 314:1547-1552.
12. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med. 1991;325:1468-1475.
13. Mancia G. Neurohumoral activation in congestive heart failure. Am Heart J. 1990;120:1532-1537.
14. Leimbach WN Jr, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation. 1986;73:913-919.
15. Genest J, Granger P, De Champlain J, Boucher R. Endocrine factors in congestive heart failure. Am J Cardiol. 1968;22:35-42.
16. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981;63:645-651.
17. Hirsch AT, Pinto YM, Schunkert H, Dzau VJ. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol. 1990;66:22D-30D.
18. Kabour A, Henegar JR, Janicki JS. Angiotensin II (AII)-induced myocyte necrosis: role of the AII receptor. J Cardiovasc Pharmacol. 1994;23: 547-553.
19. van Zwieten PA, de Jonge A. Interaction between the adrenergic and renin-angiotensin-aldosterone-systems. Postgrad Med J. 1986;62(suppl 1): 23-27.
20. Nakamaru M, Jackson EK, Inagami T. Beta-adrenoceptor-mediated release of angiotensin II from mesenteric arteries. Am J Physiol. 1986; 250:H144-H148.
21. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
22. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
23. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
24. Riegger GA, Liebau G, Kochsiek K. Antidiuretic hormone in congestive heart failure. Am J Med. 1982; 72:49-52.
25. Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;1:1385-1390.
26. Brooks VL, Keil LC, Reid IA. Role of the reninangiotensin system in the control of vasopressin secretion in conscious dogs. Circ Res. 1986;58: 829-838.
27. Pacher R. Bergler-Klein J, Globits S, et al. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol. 1993;71:1293-1299.
28. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346:732-736.
29. Pacher R, Stanek B, Hulsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996;27:633-641.
30. Kaddoura S, Poole-Wilson PA. Endothelin-1 in heart failure: a new therapeutic target? Lancet. 1996;348:418-419.
31. Brandt RR, Wright RS, Redfield MM, Burnett JC Jr. Atrial natriuretic peptide in heart failure. J Am Coll Cardiol. 1993;22(suppl A):86A-92A.
32. Raine AE, Erne P, Burgisser E, et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med. 1986;315: 533-537.
33. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
34. Floras JS. Sympathoinhibitory effects of atrial natriuretic factor in normal humans. Circulation. 1990;81:1860-1873.
35. McMurray JJ, Seidelin PH, Brown RA, Struthers AD. Noradrenaline attenuates the natriuretic effect of atrial natriuretic factor in man. Br J Clin Pharmacol. 1989;27:7-12.
36. Nakamura M, Yoshida H, Makita S, Arakawa N, Niinuma H, Hiramori K. Potent and long-lasting vasodilatory effects of adrenomedullin in humans: comparisons between normal subjects and patients with chronic heart failure. Circulation. 1997;95:1214-1221.
37. Nishikimi T, Saito Y, Kitamura K, et al. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol. 1995;26: 1424-1431.
38. Andreis PG, Neri G, Prayer-Galetti T, et al. Effects of adrenomedullin on the human adrenal glands: an in vitro study. J Clin Endocrinol Metab. 1997;82:1167-1170.
39. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73: 615-621.
40. Kaye DM, Lefkovits J, Cox H, et al. Regional epinephrine kinetics in human heart failure: evidence for extra-adrenal, nonneural release. Am J Physiol. 1995;269:H182-H188.
41. Floras JS. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol. 1993;22(suppl A): 72A-84A.
42. Hirsch AT, Dzau VJ, Creager MA. Baroreceptor function in congestive heart failure: effect on neurohumoral activation and regional vascular resistance. Circulation. 1987;75:IV36-IV48.
43. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 1995;92:3206-3211.
44. Zucker IH, Wang W, Brandle M, Schultz HD, Patel KP. Neural regulation of sympathetic nerve activity in heart failure. Prog Cardiovasc Dis. 1995; 37:397-414.
45. Ellenbogen KA, Mohanty PK, Szentpetery S, Thames MD. Arterial baroreflex abnormalities in heart failure: reversal after orthotopic cardiac transplantation. Circulation. 1989;79:51-58.
46. Gilbert EM, Olsen SL, Renlund DG, Bristow MR. Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol. 1993;71:23C-29C.
47. Bristow MR, Anderson FL, Port JD, et al. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:1024-1039.
48. Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:2426-2441.
49. Francis GS, McDonald KM, Conn JN. Neurohumoral activation in preclinical heart failure: remodeling and the potential for intervention. Circulation. 1993;87(suppl):IV90-IV96.
50. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85: 790-804.
51. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med. 1991;325: 618-624.
52. Olsson G, Rehnqvist N. Ventricular arrhythmias during the first year after acute myocardial infarction: influence of long-term treatment with metoprolol. Circulation. 1984;69:1129-1134.
53. Maisel AS. Beneficial effects of metoprolol treatment in congestive heart failure: reversal of sympathetic-induced alterations of immunologic function. Circulation. 1994;90:1774-1780.
54. Stephen SA. Unwanted effects of propranolol. Am J Cardiol. 1966;18:463-472.
55. Feuerstein GZ, Ruffolo RR Jr. Carvedilol. a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J. 1996: 17(suppl B):24-29.
56. Eichhorn EJ. Effects of bucindolol in heart failure. Am J Cardiol. 1993;71:65C-70C.
57. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817-2825.
58. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37:1022-1036.
59. Heilbrunn SM, Shah P, Valentine HA, et al. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during chronic metoprolol therapy [abstract]. Circulation. 1986;74(suppl 2):II-310.
60. 1-adrenergic receptor up-regulation [abstract]? Circulation. 1984;70(suppl 2):II-112.
61. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1997;30:27-34.
62. Pfeffer MA, Stevenson LW. Beta-adrenergic-blockers and survival in heart failure. N Engl J Med. 1996;334:1396-1397.
63. The BEST Steering Committee. Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol. 1995;75:1220-1223.
64. Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co; 1998:2810.
65. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure: MOCHA Investigators. Circulation. 1996;94:2807-2816.